The Tumor Microenvironment and Metastasis (TMM) Program was launched in 2012 to bring together a multidisciplinary team of cutting-edge immunologists and cancer biologists under a synergistic and collaborative scientific umbrella. This initiative provides for the natural evolution of the former Immunology Program that was dissolved at the end of 2011 as part of the strategic reorganization of the Cancer Center. The TMM Program comprises ten investigators with experimental interests aligned along three major flagship themes: Immunoregulation ofthe tumor microenvironment (i);Pathophysiology of metastasis (ii);and Bi-directional interaction between tumor and non-cancerous cells and their products (iii). The overarching goal of the TMM Program is to merge basic mechanistic understanding of multidisciplinary pathways of host-tumor interactions and metastatic dissemination with novel translational opportunities for disease diagnosis and (immuno)therapy. Despite the Program's recent inception, its integrated research platform has produced successful faculty recruitment, opened new opportunities for graduate education in cancer biology, considerably enhanced cancer focus, and developed extensive inter-programmatic and collaborative advances in the biology of metastasis, host-tumor cell crosstalk and immune modulation of tumor onset and progression. In terms of disease-relevance, TMM Program members are leading the development of a newly launched Ovarian Cancer Research Continuum Signature, a disease site-specific inter-programmatic initiative designed to merge basic, translational and patient oriented cancer research in a single scientific continuum. As of 2013, the TMM Program is expected to leverage a strong NCI funding base of $2.3 million, a total cancer-related peer-reviewed funding of $3.4 million (all direct costs), and currently lists 83 cancer-relevant publications, of which 29% are intra- and inter-programmatic collaborations, and 89% are inter-institutional collaborations. Building on these accomplishments, the TMM Program is on a steep, upward trajectory of research impact, scientific collaboration, and translational opportunities that leverage successful inter-institutional outreach partnerships as well as technological advances in key Shared Resources. During the next budget period, the TMM Program is ideally poised to significantly contribute to the Cancer Center's overarching mission in the continuum of cancer research by expanding scientific themes in the areas of metastatic competency and translational tumor immunology.

Public Health Relevance

The ability of tumor cells to thrive in vivo largely depends on the exploitation of cells and tissues that surround them, referred to as the microenvironment. Understanding how this immunosuppressive, proangiogenic, and pro-metastatic microenvironment is orchestrated to drive malignant progression may open new therapeutic prospects for patients with advanced and disseminated disease.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
2P30CA010815-45
Application #
8690264
Study Section
Subcommittee G - Education (NCI)
Project Start
2014-03-01
Project End
2019-02-28
Budget Start
2014-03-01
Budget End
2015-02-28
Support Year
45
Fiscal Year
2014
Total Cost
$31,554
Indirect Cost
$12,576
Name
Wistar Institute
Department
Type
DUNS #
075524595
City
Philadelphia
State
PA
Country
United States
Zip Code
19104
Fukumoto, Takeshi; Park, Pyoung Hwa; Wu, Shuai et al. (2018) Repurposing Pan-HDAC Inhibitors for ARID1A-Mutated Ovarian Cancer. Cell Rep 22:3393-3400
Bhattacharjee, Souvik; Coppens, Isabelle; Mbengue, Alassane et al. (2018) Remodeling of the malaria parasite and host human red cell by vesicle amplification that induces artemisinin resistance. Blood 131:1234-1247
Lu, Yunqi; Hu, Zhongyi; Mangala, Lingegowda S et al. (2018) MYC Targeted Long Noncoding RNA DANCR Promotes Cancer in Part by Reducing p21 Levels. Cancer Res 78:64-74
Thangavel, Chellappagounder; Boopathi, Ettickan; Liu, Yi et al. (2018) Therapeutic Challenge with a CDK 4/6 Inhibitor Induces an RB-Dependent SMAC-Mediated Apoptotic Response in Non-Small Cell Lung Cancer. Clin Cancer Res 24:1402-1414
Duperret, Elizabeth K; Liu, Shujing; Paik, Megan et al. (2018) A Designer Cross-reactive DNA Immunotherapeutic Vaccine that Targets Multiple MAGE-A Family Members Simultaneously for Cancer Therapy. Clin Cancer Res 24:6015-6027
Duperret, Elizabeth K; Wise, Megan C; Trautz, Aspen et al. (2018) Synergy of Immune Checkpoint Blockade with a Novel Synthetic Consensus DNA Vaccine Targeting TERT. Mol Ther 26:435-445
Peng, Hongzhuang; Prokop, Jeremy; Karar, Jayashree et al. (2018) Familial and Somatic BAP1 Mutations Inactivate ASXL1/2-Mediated Allosteric Regulation of BAP1 Deubiquitinase by Targeting Multiple Independent Domains. Cancer Res 78:1200-1213
Trizzino, Marco; Barbieri, Elisa; Petracovici, Ana et al. (2018) The Tumor Suppressor ARID1A Controls Global Transcription via Pausing of RNA Polymerase II. Cell Rep 23:3933-3945
Kaur, Amanpreet; Ecker, Brett L; Douglass, Stephen M et al. (2018) Remodeling of the Collagen Matrix in Aging Skin Promotes Melanoma Metastasis and Affects Immune Cell Motility. Cancer Discov :
Shastrula, Prashanth Krishna; Lund, Peder J; Garcia, Benjamin A et al. (2018) Rpp29 regulates histone H3.3 chromatin assembly through transcriptional mechanisms. J Biol Chem 293:12360-12377

Showing the most recent 10 out of 741 publications